Find a Clinical Trial

Showing 1 - 10 of 33 Trials

  • Defining the role of ctDNA monitoring in a novel, risk stratified clinical trial for PTLD.

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06954805

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in patients who have high-risk Bcell posttransplant lymphoproliferative disorder (PTLD), while those with low-risk disease will be spared of chemotherapy and treated with rituximab alone. Concurrently this study also wants to see how helpful a new blood test called circulating tumor DNA (ctDNA) is. This test has already helped doctors make better predictions and treatment decisions in other types of lymphoma. The goal is to...

  • Pembrolizumab in combination with gemcitabine for previously treated mycosis fungoides and Sezary syndrome: efficacy and characterization of immune response

    Principal Investigator:

    Larisa J Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04960618

    Population:

    Adult

    Phase:

    II
    Primary objective: Determine preliminary clinical effectiveness of pembrolizumab plus gemcitabine in previously treated MF and SS with overall response rate (ORR) using the composite global response criteria including: radiological imaging (PET/CT scans), flow cytometry and mSWAT assessments. 2. Secondary objectives: a. To estimate duration of response (DOR) of pembrolizumab plus gemcitabine in previously treated MF and SS. b. To estimate progression-free survival (PFS) pembrolizumab plus gemcitabine in previously treated MF and SS. c. To estimate overall survival (OS) of patients with...

  • Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05627245

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose expansion part (where the established dose is tested further). In the dose escalation part of this study, different people will get different doses of the study drugs tazemetostat and belinostat. The first 3 people taking part in this study...

  • A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05633615

    Population:

    Adult

    Phase:

    II
    This study is being done to answer the following question: Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients who have a partial response or stable disease after CAR T-cell therapy is follow-up visits with no further therapy. Some patients will improve their response over time, but...

  • A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04803201

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs duvelisib or CC-486 (azacitidine). The addition of duvelisib or CC-486 (azacitidine) to the usual treatment may or may not increase the chance of cancer going into remission. But, it could also cause side effects, which the study doctors want to...

  • A Phase II Trial of JAK Inhibitor added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphomas and 9p Amplified Lymphomas

    Principal Investigator:

    Seda S Tolu, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas. This includes peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphomas (CTCL), and other lymphomas (Hodgkin Lymphoma [HL], Gray Zone Lymphomas [GZL], and Primary Mediastinal B-cell Lymphoma [PMBCL]) that has become resistant to commonly available chemotherapy (refractory), or it has re- occurred after treatment (relapsed). For PTCL participants, the main goal is to see how many achieve complete...

  • A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

    Principal Investigator:

    Ran Reshef, MD, MSc

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06500273

    Population:

    Adult

    Phase:

    II
    The study aims to see if CAR T cells made from healthy donors are an effective study treatment to prevent relapse in participants who have lymphoma DNA detected in their blood by an investigational test. The study evaluates two investigational products – ALLO- 647, an antibody (protein) that may help prepare the body for receiving CAR T cells from healthy donors, and a CAR T cell study treatment called cemacabtagene ansegedleucel or cema-cel. Both ALLO-647 and cema-cel are investigational drugs and therefore not approved by the Food and Drug Administration (FDA). For reference, CAR T...

  • Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly Diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1) determine whether it is feasible to measure ctDNA in real-time during standard treatment for newly diagnosed DLBCL, and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of...

  • A Phase 2 Study of Glofitamab and Obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05783596

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma(MZL) who have not received other treatments for their lymphoma. The investigators hope that combining these two drugs can provide a more effective study treatment regimen for these diseases. In addition, pre-study treatment with obinutuzumab may reduce side effects associated with glofitamab study treatment, like cytokine release syndrome. The U.S. Food and Drug Administration (FDA) has not approved...

  • A Phase II Trial of Tazemetostat Plus Mosunetuzumab In Untreated Follicular Lymphoma

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05994235

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to test the efficacy of the combination of tazemetostat with mosunetuzumab and see what effects it has in your lymphoma. Tazemetostat is a drug that inhibits (reduces the ability of) EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system’s ability to fight it. Tazemetostat is Food and Drug Administration (FDA) approved in previously treated follicular lymphoma and currently undergoing study in other lymphomas. Mosunetuzumab is a bispecific...

Pages